ATE550022T1 - Pharmazeutische mischkristalle von celecoxib- nicotinamid - Google Patents

Pharmazeutische mischkristalle von celecoxib- nicotinamid

Info

Publication number: ATE550022T1
Authority: AT; Austria
Prior art keywords: ester; amine; api; acid; forming compound
Prior art date: 2003-02-28

Application number

AT03754445T

Other languages

English (en)

Inventor

Oern Almarsson

Hickey Magali Bourghol

Matthew Peterson

Michael Zaworotko

Brian Moulton

Nair Rodriguez-Hornedo

Original Assignee

Mcneil Ppc Inc

Univ South Florida

Univ Michigan

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-28

Filing date

2003-09-04

Publication date

2012-04-15

2003-03-03 Priority claimed from US10/378,956 external-priority patent/US20030224006A1/en

2003-09-04 Application filed by Mcneil Ppc Inc, Univ South Florida, Univ Michigan filed Critical Mcneil Ppc Inc

2012-04-15 Application granted granted Critical

2012-04-15 Publication of ATE550022T1 publication Critical patent/ATE550022T1/de

Links

239000013078 crystal Substances 0.000 title abstract 5
229960003966 nicotinamide Drugs 0.000 title 1
239000011570 nicotinamide Substances 0.000 title 1
-1 nitrate ester Chemical class 0.000 abstract 7
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 4
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 2
150000001408 amides Chemical class 0.000 abstract 2
150000001412 amines Chemical class 0.000 abstract 2
125000000524 functional group Chemical group 0.000 abstract 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 2
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
229910002651 NO3 Inorganic materials 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000001299 aldehydes Chemical class 0.000 abstract 1
229910021529 ammonia Inorganic materials 0.000 abstract 1
SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 abstract 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
238000002425 crystallisation Methods 0.000 abstract 1
230000008025 crystallization Effects 0.000 abstract 1
150000002118 epoxides Chemical class 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
150000008282 halocarbons Chemical class 0.000 abstract 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
150000002576 ketones Chemical class 0.000 abstract 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
150000002923 oximes Chemical class 0.000 abstract 1
150000002978 peroxides Chemical class 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 abstract 1
150000003141 primary amines Chemical class 0.000 abstract 1
150000003335 secondary amines Chemical class 0.000 abstract 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
150000003457 sulfones Chemical class 0.000 abstract 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
150000003512 tertiary amines Chemical class 0.000 abstract 1
150000007970 thio esters Chemical class 0.000 abstract 1
150000003568 thioethers Chemical class 0.000 abstract 1
150000003573 thiols Chemical class 0.000 abstract 1
229930192474 thiophene Natural products 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT03754445T 2003-02-28 2003-09-04 Pharmazeutische mischkristalle von celecoxib- nicotinamid ATE550022T1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US45121303P	2003-02-28	2003-02-28
US10/378,956 US20030224006A1 (en)	2002-03-01	2003-03-03	Multiple-component solid phases containing at least one active pharmaceutical ingredient
US46396203P	2003-04-18	2003-04-18
US48706403P	2003-07-11	2003-07-11
PCT/US2003/027772 WO2004078161A1 (en)	2003-02-28	2003-09-04	Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

Publications (1)

Publication Number	Publication Date
ATE550022T1 true ATE550022T1 (de)	2012-04-15

Family

ID=46243874

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03754445T ATE550022T1 (de)	2003-02-28	2003-09-04	Pharmazeutische mischkristalle von celecoxib- nicotinamid

Country Status (6)

Country	Link
EP (1)	EP1608339B8 (de)
JP (1)	JP4923182B2 (de)
AT (1)	ATE550022T1 (de)
AU (1)	AU2003272270A1 (de)
CA (1)	CA2513746C (de)
WO (1)	WO2004078161A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7790905B2 (en)	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en)	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
AU2003213719A1 (en)	2002-03-01	2003-09-16	Regents Of The University Of Michigan	Multiple-component solid phases containing at least one active pharmaceutical ingredient
IL165383A0 (en)	2002-06-21	2006-01-15	Transform Pharmaceuticals Inc	Pharmaceutical compositions with improved dissolution
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
EP1596869B1 (de)	2003-01-21	2014-06-04	New Form Pharmaceuticals Inc.	Neue co-kristallisierung
JP2007524596A (ja) *	2003-02-28	2007-08-30	トランスフォーム・ファーマシューティカルズ・インコーポレイテッド	共結晶医薬組成物
JP4842819B2 (ja) *	2003-09-04	2011-12-21	セフアロン・インコーポレーテツド	モダフィニル組成物
NZ545133A (en) *	2003-09-04	2009-12-24	Cephalon Inc	Modafinil compositions
US9682043B2 (en)	2003-12-09	2017-06-20	Medcrystalforms, Llc	Method of preparation of mixed phase co-crystals with active agents
EP2292585B1 (de)	2004-03-12	2016-04-27	Aptuit (West Lafayette), LLC	Suchen nach Festformen durch Ultraschall Kristallisierung und Cokristallisierung unter Verwendung von Ultraschall
US7507823B2 (en)	2004-05-06	2009-03-24	Bristol-Myers Squibb Company	Process of making aripiprazole particles
EP1755388B1 (de) *	2004-05-28	2010-10-06	Transform Pharmaceuticals, Inc.	Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
BRPI0712325A2 (pt)	2006-06-08	2012-01-10	Ucb Pharma Sa	processo para a preparação de co-cristais de pirrolidinonas, co-cristal, composição farmacêutica, e, uso de um co-cristal
TW200901889A (en)	2007-02-09	2009-01-16	Basf Se	Crystalline complexes of agriculturally active organic compounds
DK2114924T3 (da) *	2007-02-27	2012-04-10	Vertex Pharma	Co-krystaller og farmaceutiske sammensætninger omfattende disse
GB0706044D0 (en) *	2007-03-28	2007-05-09	Syngenta Ltd	C0-Crystals
US8173169B2 (en)	2007-07-11	2012-05-08	Hikma Pharmaceuticals	Formulation and process for the preparation of modafinil
WO2009091594A1 (en) *	2008-01-16	2009-07-23	Cephalon, Inc.	Crystalline forms of lestaurtinib
US8258155B2 (en)	2008-06-30	2012-09-04	Mutual Pharmaceutical Company, Inc.	Quinine sulfate/bisulfate solid complex; methods of making; and methods of use thereof
WO2010011926A2 (en) *	2008-07-25	2010-01-28	Bionevia Pharmaceuticals, Inc.	A novel betaine cocrystal of epalrestat
US8555875B2 (en)	2008-12-23	2013-10-15	Map Pharmaceuticals, Inc.	Inhalation devices and related methods for administration of sedative hypnotic compounds
WO2010085589A2 (en)	2009-01-22	2010-07-29	G&H Brands Llc	Desensitizing drug product
US20160016982A1 (en)	2009-07-31	2016-01-21	Thar Pharmaceuticals, Inc.	Crystallization method and bioavailability
CA2769633C (en)	2009-07-31	2017-06-06	Thar Pharma, Llc	Crystallization method and bioavailability
US9169279B2 (en)	2009-07-31	2015-10-27	Thar Pharmaceuticals, Inc.	Crystallization method and bioavailability
BR112013006651A2 (pt) *	2010-09-23	2017-07-18	Nuformix Ltd	composição e cocristal de aprepitante l-prolina
WO2012071517A2 (en)	2010-11-24	2012-05-31	Thar Pharmaceuticals, Inc.	Novel crystalline forms
CN102060755B (zh) *	2010-12-28	2012-08-22	吉林大学	一种对乙酰氨基酚药物共晶及其制备方法
US9382250B2 (en)	2011-04-22	2016-07-05	Kyorin Pharmaceutical Co., Ltd.	Method for producing complex crystal and method for screening complex crystal
KR101336143B1 (ko)	2011-09-26	2013-12-05	한밭대학교 산학협력단	클로피도그렐의 공결정
CN108640910A (zh)	2011-11-25	2018-10-12	诺弗米克斯技术有限公司	阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
KR101423630B1 (ko)	2012-02-01	2014-07-28	한밭대학교 산학협력단	비칼루타미드와 니코틴아미드의 공결정
WO2013147072A1 (ja) *	2012-03-29	2013-10-03	大鵬薬品工業株式会社	3-(15-ヒドロキシペンタデシル)-2,4,4-トリメチル-2-シクロヘキセン-1-オンの共結晶
KR101303803B1 (ko)	2012-08-02	2013-09-04	순천향대학교 산학협력단	반용매법에 의한 카바마제핀-사카린 공결정의 제조 방법 및 제조된 공결정을 포함하는 조성물
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CN103287969B (zh) *	2013-06-07	2014-11-19	力帆实业(集团)股份有限公司	轿车机舱轮罩纵梁总成吊具
CN103304476B (zh) *	2013-06-13	2015-04-01	天津大学	一种布洛芬-烟酰胺共晶的制备方法
CN104356072A (zh) *	2014-10-08	2015-02-18	哈尔滨医科大学	5-氟尿嘧啶药物共晶及其制备方法
CN104557732A (zh) *	2014-12-16	2015-04-29	哈尔滨医科大学	5-氟尿嘧啶药物共晶及其制备方法和应用
CN104557733A (zh) *	2015-01-05	2015-04-29	哈尔滨医科大学	异烟酰胺为前驱体的5-氟尿嘧啶药物共晶及其制备方法和应用
HUP1500055A1 (hu)	2015-02-09	2016-08-29	Druggability Technologies Ip Holdco Ltd	Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
CN105997919A (zh) *	2015-04-30	2016-10-12	苗怡文	一种制备解热、镇痛、抗炎药物阿司匹林肠溶片的方法
CN105732501B (zh) *	2015-10-26	2019-01-15	西北大学	一种预压片辅助研磨法制备共晶的方法
CN105330606B (zh) *	2015-11-04	2019-02-15	哈尔滨医科大学	2-氨基吡啶为前驱体的5-氟尿嘧啶药物共晶及其制备方法和应用
CN105367504A (zh) *	2015-11-04	2016-03-02	哈尔滨医科大学	吡嗪酰胺为前驱体的5-氟尿嘧啶药物共晶及其制备方法和应用
CN105481780B (zh) *	2015-12-21	2018-12-21	哈尔滨医科大学	2-氨基嘧啶为前驱体的5-氟尿嘧啶药物共晶及其制备方法和应用
WO2017208070A1 (en)	2016-05-31	2017-12-07	Grünenthal GmbH	Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
US10703760B2 (en) *	2016-08-19	2020-07-07	Celgene International Ii Sàrl	Morphic forms of marizomib and uses thereof
RU2770033C2 (ru)	2016-11-28	2022-04-14	Целликс Био Прайвет Лимитед	Композиции и способы лечения инфекционных заболеваний ротовой полости
WO2018222713A1 (en) *	2017-05-30	2018-12-06	Theaprin Pharmaceuticals, Inc.	Sublingual formulation with water-soluble cocrystals of acetylsalicylic acid with citric acid, sodium bicarbonate, and l-theanine for the treatment of acute myocardial infarction
BR112020011625A2 (pt) *	2017-12-11	2020-11-17	Artelo Biosciences, Inc.	formas sólidas de canabidiol e usos das mesmas
US11319311B2 (en)	2018-02-13	2022-05-03	Transgenex Nanobiotech, Inc.	Crystalline forms of Actinomycin D for treatment of cancer
JP7590755B2 (ja) *	2020-10-27	2024-11-27	全薬工業株式会社	イブプロフェンとトラネキサム酸との結晶
CN115141136B (zh) *	2021-03-31	2023-06-20	中国人民解放军军事科学院军事医学研究院	特考韦瑞药的共晶及其制备方法
CN114031515B (zh) *	2021-11-29	2022-10-21	河北大学	一种对乙酰氨基酚-布洛芬药物共晶及其制备方法
CA3262434A1 (en)	2022-07-20	2025-06-12	Asahi Kasei Kabushiki Kaisha	Hyaluronic acid derivative drug composition and drug composition
WO2024201281A1 (en) *	2023-03-28	2024-10-03	Wonderfeel	Methods and compositions for treatment of pain

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
GB8500862D0 (en) *	1985-01-14	1985-02-20	Tate & Lyle Plc	Composition
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5780058A (en)	1995-07-21	1998-07-14	Alza Corporation	Oral delivery of discrete units
US6132420A (en)	1996-02-02	2000-10-17	Alza Corporation	Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
MY125849A (en)	1997-07-25	2006-08-30	Alza Corp	Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
AU1623099A (en)	1997-12-22	1999-07-12	Alza Corporation	Rate controlling membranes for controlled drug delivery devices
WO1999033446A1 (en)	1997-12-29	1999-07-08	Alza Corporation	Osmotic delivery system with membrane plug retention mechanism
AU1937099A (en)	1997-12-31	1999-07-19	Alza Corporation	Osmotic drug delivery monitoring system and method
US6245357B1 (en)	1998-03-06	2001-06-12	Alza Corporation	Extended release dosage form
US6365185B1 (en)	1998-03-26	2002-04-02	University Of Cincinnati	Self-destructing, controlled release peroral drug delivery system
IL142807A0 (en)	1998-11-02	2002-03-10	Alza Corp	Controlled delivery of active agents
US6342249B1 (en)	1998-12-23	2002-01-29	Alza Corporation	Controlled release liquid active agent formulation dosage forms
UA74539C2 (en)	1999-12-08	2006-01-16	Pharmacia Corp	Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
EP1248869A2 (de) *	2000-01-07	2002-10-16	Transform Pharmaceuticals, Inc.	Hochdurchsatzherstellung sowie bestimmung und analyse verschiedener fester formen
AU2002334987A1 (en) *	2001-10-15	2003-04-28	The Regents Of The University Of Michigan	Systems and methods for the generation of crystalline polymorphs
AU2003213719A1 (en) *	2002-03-01	2003-09-16	Regents Of The University Of Michigan	Multiple-component solid phases containing at least one active pharmaceutical ingredient
JP4633588B2 (ja) *	2005-09-20	2011-02-16	Ｋｄｄｉ株式会社	気象データ配信装置および局域気象データ配信システムならびに同システムにおける気象データ推定方法

2003
- 2003-09-04 AT AT03754445T patent/ATE550022T1/de active
- 2003-09-04 JP JP2006552403A patent/JP4923182B2/ja not_active Expired - Fee Related
- 2003-09-04 EP EP03754445A patent/EP1608339B8/de not_active Expired - Lifetime
- 2003-09-04 AU AU2003272270A patent/AU2003272270A1/en not_active Abandoned
- 2003-09-04 CA CA2513746A patent/CA2513746C/en not_active Expired - Lifetime
- 2003-09-04 WO PCT/US2003/027772 patent/WO2004078161A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP1608339B8 (de)	2012-04-25
CA2513746A1 (en)	2004-09-16
HK1083770A1 (en)	2006-07-14
AU2003272270A8 (en)	2004-09-28
EP1608339A1 (de)	2005-12-28
WO2004078161A1 (en)	2004-09-16
JP4923182B2 (ja)	2012-04-25
CA2513746C (en)	2012-08-28
AU2003272270A1 (en)	2004-09-28
EP1608339B1 (de)	2012-03-21
JP2007507554A (ja)	2007-03-29

Publication	Publication Date	Title
ATE550022T1 (de)	2012-04-15	Pharmazeutische mischkristalle von celecoxib- nicotinamid
WO2004078163A3 (en)	2005-01-20	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
Park et al.	2015	Persulfides: current knowledge and challenges in chemistry and chemical biology
HN2002000156A (es)	2003-11-27	Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
RU2016150386A (ru)	2018-06-21	Гетероциклические модуляторы транспортеров атф-связывающей кассеты
IS7391A (is)	2004-08-09	ACC hindrar
BRPI0408703A (pt)	2006-03-07	derivados de estrogênio como inibidores da esteróide sulfatase
BR0114832A (pt)	2004-07-06	Composição pesticida
EA200401202A1 (ru)	2005-02-24	Сульфонилпроизводные в качестве новых ингибиторов гистон-деацетилазы
EP4289443A3 (de)	2024-02-28	Stabilisierte antikörperproteinlösungen
NZ503788A (en)	2002-11-26	4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases
Iciek et al.	2022	Reactive sulfur compounds in the fight against COVID-19
EA200601274A1 (ru)	2007-02-27	Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат
ID26972A (id)	2001-02-22	TIOESTER ASAM S-SUBSTITUSI 11β-BENZALDOKSIN ESTRA-4,9-DIENAKARBONAT, PROSES UNTUK MEMBUAT DAN SEDIAAN FARMASI YANG TERDIRI DARI SENYAWA INI
HK1085137A (en)	2006-08-18	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
Khodade et al.	2025	Arylsulfonothioates: Thiol-activated donors of hydropersulfides which are excreted to maintain cellular redox homeostasis or retained to counter oxidative stress
BR112022009318A2 (pt)	2022-08-09	Partícula de fertilizante núcleo-casca
BRPI0821215A2 (pt)	2014-10-07	Composição farmacêutica, contendo um derivado de n-fenil pirazol e glicofurol, utilização para o preparo de um medicamento veterinário tópico para combater as pulgas
EA200300926A1 (ru)	2004-04-29	Новый способ промышленного синтеза метил дисложного эфира 5-амино-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов
Almarsson et al.	2011	Pharmaceutical co-crystal compositions
Depetter et al.	2018	Assessment of the trifluoromethyl ketone functionality as an alternative zinc-binding group for selective HDAC6 inhibition
DK1165485T3 (da)	2004-07-19	Fremgangsmåde til fremstilling af pesticidmellemprodukter
DE602004021854D1 (de)	2009-08-13	Pharmazeutisches präparat für die mundhöhle
BRPI0716601A2 (pt)	2013-09-17	compostos de heteroaromÁticos tendo atividade biolàgica agonista de receptor de esfingosina-1-fosfato(s1p)
BR0103070A (pt)	2002-08-06	Compostos benzotiadiazina, processo para sua preparação e composições farmacêuticas contendo os mesmos